Elizabeth (Beth) Garner is a seasoned strategic- and business-minded pharmaceutical executive and corporate board member with a career-long focus on addressing unmet medical needs that affect women’s health and quality of life. Born and raised in Nigeria, she brings a global view to her work in both the corporate and non-profit worlds. With seventeen years of experience, Dr. Garner has wide expertise in product development, including clinical trial design and conduct, US/ex-US regulatory and FDA Advisory Committee strategy, medical affairs, and due diligence assessment of early- to late-stage therapeutic, device, and diagnostic product candidates.

Dr. Garner is currently the CEO of a stealth start-up company focused on targeted therapies for women’s health disorders. Most recently, she was Chief Scientific Officer of Ferring Pharmaceuticals US, a mid-size global company focused on reproductive and maternal health, microbiome and gastrointestinal therapeutics, and uro-oncology.  Her prior C-suite roles include Chief Medical Officer (CMO) of ObsEva and Agile Therapeutics.

Dr. Garner has also held leadership roles at Myriad Genetics, Abbott Laboratories, and Merck Research Labs, where she was a contributor on the Gardasil and Gardasil9 vaccines. Dr. Garner joined the Medicines360 Board of Directors in March, 2022. She is also on the Board of Kezar Life Sciences (KZR) and is the BOD chair of NUA Surgical, a start-up company dedicated to creating innovative surgical solutions in obstetrics and gynecology.

She is the Immediate Past President of the American Medical Women’s Association (AMWA), a professional organization whose mission is to advance women physicians, advocate for equity, and ensure excellence in healthcare. Beth received joint M.D. and M.P.H. degrees from Harvard Medical and Public Health Schools, trained in obstetrics and gynecology at Brigham and Women’s (BWH)/Massachusetts General Hospitals, and completed a fellowship in gynecologic oncology at BWH/Dana Farber Cancer Institute.